Cita APA

Hontecillas Prieto, L., & Provencio Pulla, M. (2024). CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

Citación estilo Chicago

Hontecillas Prieto, Lourdes, y Mariano Provencio Pulla. CD8+ NKs As a Potential Biomarker of Complete Response and Survival With Lenalidomide Plus R-GDP in the R2-GDP-GOTEL Trial in Recurrent/refractory Diffuse Large B Cell Lymphoma. 2024.

Cita MLA

Hontecillas Prieto, Lourdes, y Mariano Provencio Pulla. CD8+ NKs As a Potential Biomarker of Complete Response and Survival With Lenalidomide Plus R-GDP in the R2-GDP-GOTEL Trial in Recurrent/refractory Diffuse Large B Cell Lymphoma. 2024.